Okonji, Osaretin ChristabelLedesma, Jorge RZhang, MeixinLiew, Mei FongDominguez, Regina-Mae Villanueva2026-08-122026-08-122026Ledesma, J.R., Zhang, M., Liew, M.F., Dominguez, R.M.V., Whikehart, S.M.L., Verma, M., Ma, J., Movo, A., Chu, H.T., Ostroff, S.M. and He, J., 2026. Global, regional, and national burden of tuberculosis and multidrug-resistant tuberculosis by HIV status, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023. The Lancet infectious diseases.https://doi.org/10.1016/S1473-3099(26)00295-1https://hdl.handle.net/10566/25131Tuberculosis (TB) is the leading global cause of death from a single infectious agent. Recent reductions in global health funding have threatened TB control, making comprehensive assessment of TB, HIV-related TB, and drug-resistant TB burdens before these disruptions essential for shaping effective responses. The WHO End TB Strategy sets targets of a 95% reduction in TB deaths and a 90% reduction in TB incidence between 2015 and 2035. Using results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023, this study aims to assess the burden of TB and multidrug-resistant TB (MDR-TB) across 204 countries and territories, and to evaluate progress towards the WHO End TB incidence and mortality targets.enTuberculosis (TB)Multidrug-resistant tuberculosis (MDR-TB)HIVHIV-associated tuberculosisGlobal Burden of Disease (GBD)Article